Vivani Medical Appoints Anthony Baldor as Chief Financial Officer
vivani | June 11, 2025
Read More
Vivani Medical to Present at the 2025 BIO International Convention
vivani | June 10, 2025
Read More
Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders
vivani | May 29, 2025
Read More
Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
vivani | May 13, 2025
Read More
Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
vivani | May 7, 2025
Read More
Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company
vivani | April 16, 2025
Read More
Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity
vivani | April 15, 2025
Read More
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
vivani | March 31, 2025
Read More
Vivani Medical Announces $8.25M Private Placement Equity Financing
vivani | March 27, 2025
Read More
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
| December 4, 2024
Read More
Blog Navigation
Contact Us
To learn more about Vivani, and to learn more about our strategic focus on NPM-139 (semaglutide implant), please fill out this form.